Académique Documents
Professionnel Documents
Culture Documents
2013, 4 (4)
www.irjponline.com
Review Article
INTRODUCTION
The prefix nano has found in last decade an ever-increasing
application to different fields of the knowledge. Nanoscience,
nanotechnology, nanomaterials or nanochemistry are only a
few of the new nano-containing terms that occur frequently in
scientific reports, in popular books as well as in newspapers
and that have become familiar to a wide public, even of nonexperts. The prefix comes from the ancient Greek
through the Latin nanus meaning literally dwarf and by
extension, very small. Within the convention of International
System of Units (SI) it is used to indicate a reduction factor
of 109 times. So, the nanosized world is typically measured in
nanometers (1nm corresponding to 10-9 m) and it
encompasses systems whose size is above molecular
dimensions and below macroscopic ones (generally > 1 nm
and < 100 nm).
Nanotechnology is the science of the small; the very small. It
is the use and manipulation of matter at a tiny scale. At this
size, atoms and molecules work differently, and provide a
variety of surprising and interesting uses. Nanotechnology
and Nanoscience studies have emerged rapidly during the
past years in a broad range of product domains. It provides
opportunities for the development of materials, including
those for medical applications, where conventional
techniques may reach their limits. Nanotechnology should
not be viewed as a single technique that only affects specific
areas. Although often referred to as the tiny science,
nanotechnology does not simply mean very small structures
and products. Nanoscale features are often incorporated into
bulk materials and large surfaces. Nanotechnology represents
the design, production and application of materials at atomic,
molecular and macromolecular scales, in order to produce
new nanosized materials.1 Pharmaceutical nanoparticles are
defined as solid, submicron-sized (less than 100 nm in
diameter) drug carrier that may or may not be biodegradable.
The term nanoparticle is a combined name for both
nanospheres and nanocapsules. Nanospheres are matrix
system in which drug is uniformly dispersed, while
nanocapsules are the system in which the drug is surrounded
by a unique polymeric membrane.
Figure 1: Types of polymeric nanoparticles: According to the structural organization biodegradable nanoparticles are classified as Nanocapsules and
nanospheres. The drug molecules are either entrapped inside or adsorbed on the surface.
Page 48
Page 49
Chemical Reactions
Chemical reactions, like polymerizations, are one way to
produce nanoparticles; however they are normally not used
for the production of drug nanoparticles consisting of pure
API.
These techniques are commercially very important e.g. for
the production of pharmaceutical coating materials in the
form of latex dispersions. Chemical reactions can also be
used to manufacture polymeric nanoparticles consisting of a
matrix forming polymer in which the API is embedded. The
drug load of such particles is normally significantly lower
than 100% therefore they have to be distinguished from drug
nanoparticles produced via standard particle size reduction
techniques.
Bottom-up Approaches
Bottom-up approaches start with drug molecules in solution.
By changing the conditions of the system in solution, the
drug molecules start to precipitate in larger formations. In the
classical precipitation process, the poorly soluble API is
dissolved in a water miscible organic solvent. The
precipitation is induced by mixing the drug solution with an
aqueous phase. This is often referred to as the solvent/
antisolvent approach. One approach was already developed
in the 1980s by Sucker and colleagues. The principle of
classical precipitation has been then further developed by
several academic and industrial research groups. Later also
more and more advanced precipitation technologies have
been introduced. These technologies are also referred to as
particle engineering technologies. One interesting approach is
known as Evaporative Precipitation into Aqueous Solution
(EPAS). For this process, the API is dissolved in an organic
solvent which is not miscible with water. The drug
solution is sprayed into heated water resulting in an
immediate evaporation of the organic solvent, thus drug
nanoparticles are formed instantaneously. Spray-freezing into
liquid (SFL) and ultrarapid freezing (URF) are alternative
particle engineering processes developed by the same
research group.
Top-down Approaches
In contrast to the bottom-up technologies, one can also start
with large API particles and break them down to small drug
nanoparticles. Therefore, this process type is regarded as topdown technology. Currently particle size reduction
technologies of this type are by far commercially the most
important and successful. A very important technology is
Purpose
To determine the drug loading capacity & drug release. 59
To study antinociceptive activity and blood brain delivery. 60
To enhance effective delivery of Adriamycin. 61
To increase the amount of drug release with respect to pure drug. 62
To increase the local concentration of tamoxifen in estrogen receptor positive breast cancer cells. 63
To form stable suspension of submicron particles of Cyclosporin A. 64
To study the effect of formulation variables on size distribution. 65
Capable of releasing the drug in a slow sustained manner. 66
For effective delivery of drug to solid tumors. 67
To increase oral bioavailability of Estradiol. 68
To improve skin penetration of the poorly absorbed drug Cyproterone. 69
For coating curcumin onto a metal stent by electrophoretic deposition thereby avoiding problem with restenosis after
percutaneous coronary intervention.70
To decrease the systemic toxicity of ropivacaine. 71
For sustained release of Didanosine. 72
Increased bioavailability of lamivudine is observed when tested in AIDS patients. 73
To enhance effective delivery of poorly water soluble drug simvastatin. 74
To improve oral bioavailability of Doxorubicin. 75
To improve oral bioavailability and to show reduced nephrotoxicity compared to intravenous fungizone. 76
To formulate Rifampicin for aerosol delivery in a dry powder, which is suited for shelf stability, effective dispersibility and
extended release with local lung and systemic drug delivery. 77
To enhance the transport of curcumin to brain and to enhance the delivery system to cross the BBB. 78
Page 54
API
Doxorubicin
Amphotericin B
Amphotericin B
Amphotericin B
Sirolimus
Aprepitatnt
Fenofibrate
Fenofibrate
Company
Gilead Sciences.
Gilead Sciences
Alza
Elan
Elan/Wyeth
Elan/Merck
Elan/Abbot.
First Horizon Pharmaceuticals
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
Sapra P., Tyagi P., Allen TM. Ligand-targeted liposomes for cancer
treatment. Current Drug Delivery. 2005; 2:369-381. http://dx.doi.org
/10.2174/156720105774370159 PMid:16305440
Mohanraj VJ., Chen Y. Nanoparticles a review. Tropical Journal of
Pharmaceutical Research. 2006; 5:561-573.
Yadav C., Kumari A., Yadav SK., Subhash C. Biodegradable polymeric
nanoparticles based drug delivery systems review. Colloids and Surfaces
B:
Biointerfaces.
2010;
75:1-18.
http://dx.doi.org/
10.1016/j.colsurfb.2009.09.001 PMid:19782542
Hett A. Nanotechnology: small matters, many unknown. Swiss Re, Risk
Perception Series, Zurich 2004.
Kohler M., Fritzsche W. Nanotechnology, an introduction to
nanostructuring. Wiley-VCH. 2007; 2.
Tomalia DA. Birth of a new macromolecular architecture: Dendrimers
as quantized building blocks for nanoscale synthetic organic chemistry.
Aldrichimica Acta. 2004; 37:39-57.
Wiener EC., Brechbiel MW., Brothers H., Magin RL., Gansow
OA.,Tomalia DA. Dendrimer-based metal chelates: a new class of
magnetic resonance imaging contrast agents. Magnetic Resonance in
Medicine. 1994; 31:1-8. http://dx.doi.org/10.1002/mrm.1910310102
Li Y., Cheng Y., Xu T. Design, synthesis and potent pharmaceutical
applications of glycodendrimers: a mini review. Current Drug Discovery
Technology.2007;4:246-254.http://dx.doi.org/10.2174/157016307
783220503
Fu HL., Cheng SX., Zhang XZ., Zhuo RX. Dendrimers/DNA complexes
encapsulated in a water soluble polymer and supported on fast degrading
star poly (DL-lactide) for localized gene delivery. Journal of Control
Release.2007;124:181-188.http://dx.doi.org/10.1016/j.jconrel.20
07.08.031 PMid:17900738
Cheng Y., Wang J., Rao T., He X., Xu T. Pharmaceutical applications of
dendrimers: promising nanocarriers for drug delivery. Frontiers in
Bioscience. 2008; 13:1447-1471. http://dx.doi.org/10.2741/2774
PMid:17981642
Mecke A., Uppuluri S., Sassanella TM., Lee DK., Ramamoorthy A.,
Baker JR. Direct observation of lipid bilayer disruption by poly
(amidoamine) dendrimers. Chemistry and Physics of Lipids. 2004;
132:3-14.
http://dx.doi.org/10.1016/j.chemphyslip.2004.09.001
PMid:15530443
Goldberg M., Langer R., Jia X. Nanostructured materials for
applications in drug delivery and tissue engineering. Journal of
Biomaterials Science, Polymer. 2007; 18:241-268. http://dx.doi.org/
10.1163/156856207779996931
Larson DR., Zipfel WR., Williams RM., Clark SW., Bruchez MP., Wise
FW. Water-soluble quantum dots for multiphoton fluorescence imaging
in vivo. Science. 2003; 300:1434-1436. http://dx.doi.org/10.1126
/science.1083780 PMid:12775841
Kreuter J. Nanoparticles. In Colloidal drug delivery systems, J, K., Ed.
Marcel Dekker: New York. 1994; 219-342.
Mschwitzer J. Particle Size Reduction Technologies in the
Pharmaceutical Development Process. American Pharmaceutical
Review. 2010; 54-59.
Murtaza G. Formulation of Nimesulide Floating Microparticles Using
Low-viscosity Hydroxypropyl Methylcellulose. Tropical Journal of
Pharmaceutical Research. 2010; 9:293-299.
Rolland JP., Maynor BW., Euliss LE., Exner AE., Denison GM.,
DeSimone JM. Direct fabrication and harvesting of monodisperse,
shape-specific Nano biomaterials. Journal of the American Chemical
Society. 2005; 127:10096-10100. http://dx.doi.org/10.1021/ja051977c
PMid:16011375
Kompella UB., Bandi N., Ayalasomayajula SP. Poly (lactic acid)
nanoparticles for sustained release of budesonide. Drug Delivery
Technology. 2001; 1:1-7.
Ravi MN., Bakowsky U., Lehr CM. Preparation and characterization of
cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;
25:1771-1777. http://dx.doi.org/10.1016/j.biomaterials.2003.08.069
Li YP., Pei YY., Zhou ZH., Zhang XY., Gu ZH., Ding J., Zhou JJ., Gao
XJ., PEGylated polycyanoacrylate nanoparticles as tumor necrosis
factor-alpha carriers. Journal of Control Release. 2001; 71:287-296.
http://dx.doi.org/10.1016/S0168-3659(01)00235-8
Zambaux M., Bonneaux F., Gref R., Maincent P., Dellacherie E., Alonso
M., Labrude P., Vigneron C. Influence of experimental parameters on
the characteristics of poly(lactic acid) nanoparticles prepared by double
emulsion method. Journal of Control Release. 1998; 50:31-40.
http://dx.doi.org/10.1016/S0168-3659(97)00106-5
Niwa T., Takeuchi H., Hino T., Kunou N., Kawashima Y. Preparation of
biodegradable nanoparticles of water soluble and insoluble drugs with
D,L lactide/ glycolide copolymer by a novel spontaneous emulsification
solvent diffusion method and the drug release behaviour. Journal of
Control Release. 1993; 25:89-98. http://dx.doi.org/10.1016/01683659(93)90097-O
Page 55
Page 56
70.
71.
72.
73.
74.
75. Kalaria DR., Sharma G., Beniwal V., Ravi Kumar MNV. Design of
biodegradable nanoparticles for oral delivery of Doxorubicin: In vivo
pharmacokinetics and toxicity studies in rats. Pharmaceutical Research.
2009;
26:492-501.http://dx.doi.org/10.1007/s11095-008-9763-4
PMid:18998202
76. Italia JL., Yahya MM., Singh D., Ravi Kumar MNV. Biodegradable
nanoparticles improve oral bioavailability of Amphotericin B and show
reduced nephrotoxicity compared to intravenous Fungizone.
Pharmaceutical Research. 2009; 26:1324-1331. http://dx.doi.org/
10.1007/s11095-009-9841-2 PMid:19214716
77. Jean CS., Danielle JP., Lucila GC., Jarod LV., David D.,Charles AP.,
Katharina JE., Anthony JH., David AE. Formulation and
Pharmacokinetics of self-assembled Rifampicin nanoparticle systems for
pulmonary delivery. Pharmaceutical Research. 2009; 26:1847-1855.
http://dx.doi.org/10.1007/s11095-009-9894-2 PMid:19407933
78. Min S., Yan G., Chenyu G., Fengliang C., Zhimei S., Yanwei X., Aihua
Y., Aiguo L., Guangxi Z. Enhancement of transport of Curcumin to
brain in mice by Poly (n-butylcyanoacrylate) nanoparticle. Journal of
Nanoresearch. 2010; 12:3111-3122.
Cite this article as:
Konwar Ranjit, Ahmed Abdul Baquee. Nanoparticle: an overview of
preparation, characterization and application. Int. Res. J. Pharm. 2013;
4(4):47-57
Page 57